Novartis Pharms Corp Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NOVARTIS PHARMS CORP, and what generic alternatives to NOVARTIS PHARMS CORP drugs are available?
NOVARTIS PHARMS CORP has two approved drugs.
There are eleven US patents protecting NOVARTIS PHARMS CORP drugs.
There are one hundred and eighty-seven patent family members on NOVARTIS PHARMS CORP drugs in fifty countries and thirty-one supplementary protection certificates in fourteen countries.
Summary for Novartis Pharms Corp
International Patents: | 187 |
US Patents: | 11 |
Tradenames: | 2 |
Ingredients: | 2 |
NDAs: | 2 |
Drugs and US Patents for Novartis Pharms Corp
Expired US Patents for Novartis Pharms Corp
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-002 | Mar 30, 2015 | 6,465,504 | See Plans and Pricing |
Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-001 | Mar 30, 2015 | 6,465,504 | See Plans and Pricing |
Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-003 | Mar 30, 2015 | 6,596,750 | See Plans and Pricing |
Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-003 | Mar 30, 2015 | 6,465,504 | See Plans and Pricing |
Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-001 | Mar 30, 2015 | 6,596,750 | See Plans and Pricing |
Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-002 | Mar 30, 2015 | 6,596,750 | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for NOVARTIS PHARMS CORP drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 90 mg and 360 mg | ➤ Subscribe | 2015-10-19 |
➤ Subscribe | Tablets | 180 mg | ➤ Subscribe | 2016-04-28 |
➤ Subscribe | Tablets | 180 mg | ➤ Subscribe | 2015-10-23 |
International Patents for Novartis Pharms Corp Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Croatia | P20140274 | See Plans and Pricing |
Taiwan | I686215 | See Plans and Pricing |
South Korea | 102159601 | See Plans and Pricing |
Hong Kong | 1175465 | See Plans and Pricing |
Spain | 2879550 | See Plans and Pricing |
Japan | 6482462 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Novartis Pharms Corp Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2340828 | LUC00195 | Luxembourg | See Plans and Pricing | PRODUCT NAME: SACUBITRIL ET VALSARTAN, SOUS FORME DE COMPLEXE DE SEL DE SODIUM SACUBITRIL VALSARTAN, C'EST-A-DIRE (((S)-N-VALERYL-N-((2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL)-METHYL)-VALINE) ((2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-ESTER ETHYLIQUE D'ACIDE PENTANOIQUE))NA3 X H2O, DANS LEQUEL X EST 0 A 3; AUTHORISATION NUMBER AND DATE: EU/1/15/1058 20151123 |
1948158 | 1690020-1 | Sweden | See Plans and Pricing | PRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123 |
2340828 | PA2021502 | Lithuania | See Plans and Pricing | PRODUCT NAME: SAKUBITRILAS/VALSARTANAS, KAIP SAKUBITRILO VALSARTANO NATRIO DRUSKOS KOMPLEKSAS, T.Y. (((S)-N-VALERIL-N-((2'-(1H-TETRAZOL-5-IL)-BIFENIL-4-IL)-METIL)-VALINAS)((2R,4S)-5-BIFENIL-4-IL-4-(3-KARBOKSI-PROPIONILAMINO)-2-METIL-PENTANO RUGSTIES ETILO ESTERIS)NA3; REGISTRATION NO/DATE: EU/1/15/1058 20151119 |
0914118 | PA2007001,C0914118 | Lithuania | See Plans and Pricing | PRODUCT NAME: DEFERASIROXUM; REGISTRATION NO/DATE: EU/1/06/356/001 2006-08-28, EU/1/06/356/002 2006-08-28, EU/1/06/356/003 2006-08-28, EU/1/06/356/004 2006-08-28, EU/1/06/356/005 2006-08-28, EU/1/06/356/00 20060828 |
1948158 | C 2016 017 | Romania | See Plans and Pricing | PRODUCT NAME: SACUBITRIL/VALSARTAN, SUB FORMA DE COMPLEX DE SARURI DE SODIU; NATIONAL AUTHORISATION NUMBER: EU/1/15/1058/001-016; DATE OF NATIONAL AUTHORISATION: 20151119; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/15/1058/001-016; DATE OF FIRST AUTHORISATION IN EEA: 20151119 |
1948158 | 122016000038 | Germany | See Plans and Pricing | PRODUCT NAME: SACUBITRIL/VALSARTAN, ALS SACUBITRIL VALSARTAN NATRIUM SALZKOMPLEX, D.H. TRINATRIUM-(3-((1 S,3R)-1-BIPHENYL-4-YLMETHYL-3-ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONAT-(S)-3'-METHYL-2'-(PENTANOYL-(2"-(TETRAZOL-5-YLAT)BIPHENYL-4'-YLMETHYL)AMINO)BUTYRAT)-HEMIPENTAHYDRAT.; REGISTRATION NO/DATE: EU/1/15/1058 20151119 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.